| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10751305 | TARO PHARMS | Solid-forming topical formulations for pain control |
Jan, 2031
(7 years from now) | |
| US10350180 | TARO PHARMS | Solid-forming local anesthetic formulations for pain control |
Jan, 2031
(7 years from now) | |
| US10603293 | TARO PHARMS | Solid-forming local anesthetic formulations for pain control |
Jan, 2031
(7 years from now) | |
Pliaglis is owned by Taro Pharms.
Pliaglis contains Lidocaine; Tetracaine.
Pliaglis has a total of 3 drug patents out of which 0 drug patents have expired.
Pliaglis was authorised for market use on 29 June, 2006.
Pliaglis is available in cream;topical dosage forms.
The generics of Pliaglis are possible to be released after 14 January, 2031.
Drugs and Companies using LIDOCAINE; TETRACAINE ingredient
Market Authorisation Date: 29 June, 2006
Treatment: NA
Dosage: CREAM;TOPICAL
More Information on Dosage
PLIAGLIS family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic